Arbutus Biopharma Corp (ABUS)
| Market Cap | 960.03M+9.0% |
| Revenue (ttm) | 181.72M+1078.8% |
| Net Income | 153.05M+382.1% |
| EPS | 0.78+374.4% |
| Shares Out | 197.54M |
| PE Ratio | 6.15 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 11,635,262 |
| Open | 4.85 |
| Previous Close | 4.85 |
| Day's Range | 4.80 - 4.88 |
| 52-Week Range | 3.50 - 5.45 |
| Beta | 0.62 |
| Analysts | Buy |
| Price Target | 8.50(+74.90%) |
| Earnings Date | Nov 16, 2026 |
Insiders here have filed 12 Form 4s in the last 90 days, but all of them are share awards, grants or other non-market transactions. Those are compensation, not a decision to buy, so they are not scored.
$ABUS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ABUS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ABUS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ABUS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ABUS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ABUS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ABUS
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $25.58M |
| IWMiShares Russell 2000 ETF | $19.65M |
| XBIState Street SPDR S&P Biotech ETF | $14.17M |
| VXFVanguard Extended Market ETF | $9.31M |
| IWOiShares Russell 2000 Growth ETF | $7.48M |
| IBBiShares Biotechnology ETF | $5.84M |
Estimated from each fund’s disclosed top holdings × AUM
ABUS Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ABUS’s recent data — informational, not investment advice